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The toxicity (IC50) of a series of mononuclear ruthenium complexes containing
bis[4(4′-methyl-2,2′-bipyridyl)]-1,n-alkane (bbn) as a tetradentate ligand against three
eukaryotic cell lines—BHK (baby hamster kidney), Caco-2 (heterogeneous human
epithelial colorectal adenocarcinoma) and Hep-G2 (liver carcinoma)—have been
determined. The results demonstrate that cis-α-[Ru(Me4phen)(bb7)]
2+ (designated
as α-Me4phen-bb7, where Me4phen = 3,4,7,8-tetramethyl-1,10-phenanthroline)
showed little toxicity toward the three cell lines, and was considerably less
toxic than cis-α-[Ru(phen)(bb12)]
2+ (α-phen-bb12) and the dinuclear complex
[{Ru(phen)2}2{µ-bb12}]
4+. Fluorescence spectroscopy was used to study the binding
of the ruthenium complexes with human serum albumin (HSA). The binding of
α-Me4phen-bb7 to the macrocyclic host molecule cucurbit[10]uril (Q[10]) was examined
by NMR spectroscopy. Large upfield 1H NMR chemical shift changes observed for the
methylene protons in the bb7 ligand upon addition of Q[10], coupled with the observation
of several intermolecular ROEs in ROESY spectra, indicated that α-Me4phen-bb7 bound
Q[10] with the bb7 methylene carbons within the cavity and the metal center positioned
outside one of the portals. Simple molecular modeling confirmed the feasibility of the
binding model. An α-Me4phen-bb7-Q[10] binding constant of 9.9 ± 0.2 × 10
6 M−1 was
determined by luminescence spectroscopy. Q[10]-encapsulation decreased the toxicity
of α-Me4phen-bb7 against the three eukaryotic cell lines and increased the binding
affinity of the ruthenium complex for HSA. Confocal microscopy experiments indicated
that the level of accumulation of α-Me4phen-7 in BHK cells is not significantly affected by
Q[10]-encapsulation. Taken together, the combined results suggest that α-Me4phen-7
could be a good candidate as a new antimicrobial agent, and Q[10]-encapsulation could
be a method to improve the pharmacokinetics of the ruthenium complex.
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INTRODUCTION
Due to the increasing resistance of bacteria, particularly Gram-
negative species, to the range of drugs currently in clinical
use there is significant interest in developing new antimicrobial
agents (Boucher et al., 2009). While there is an on-going effort to
produce new antimicrobial drugs based upon analogs of known
scaffolds, e.g., β-lactam antibiotics (Boucher et al., 2009), there
is an increasing focus on the use of metal-based compounds
(Richards et al., 2009; Neelakantan et al., 2010; Ng et al., 2013;
Pandrala et al., 2013). In particular, and reflecting a greater
recognition of their therapeutic potential (Bergamo and Sava,
2007; Moucheron, 2009; Süss-Fink, 2010; Gill and Thomas, 2012;
Li et al., 2018), has been the growing development of ruthenium
complexes as potential antimicrobial agents (Li et al., 2015a;
Southam et al., 2017; Mital and Ziora, 2018). Dwyer and co-
workers demonstrated more than 60 years ago the activity of
mononuclear polypyridylruthenium(II) complexes against both
Gram-positive and Gram-negative bacteria (Dwyer et al., 1952,
1969). However, it has only been over the last 10 years that
there has been renewed and widespread interest in examining
the antimicrobial properties of a broad range of ruthenium
complexes (Kumar et al., 2009, 2016; Bolhuis et al., 2011; Li et al.,
2011, 2013a, 2014; Shobha Devi et al., 2013; Gorle et al., 2016).
Previous studies from our group have examined the
antimicrobial properties of di-, tri- and tetra-nuclear
polypyridylruthenium(II) complexes in which the metal
centers are linked by the bis[4(4′-methyl-2,2′-bipyridyl)]-
1,n-alkane ligand (“bbn”; see Figure 1) (Li et al., 2011, 2016;
Gorle et al., 2014). These oligonuclear ruthenium complexes
showed excellent activity against Gram-positive bacteria, and
maintained the activity against current drug-resistant strains
such as methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant enterococci (VRE) (Gorle et al., 2016).
However, the oligonuclear complexes showed variable activity to
Gram-negative strains, with a number of species being essentially
resistant to the ruthenium complexes (Gorle et al., 2016).
As the toxicity to both bacterial and eukaryotic cells
increased with the number of ruthenium centers in the
oligonuclear complex (Li et al., 2012, 2015b), we sought
to examine mononuclear complexes that contained the bbn
moiety as a tetradentate ligand—[Ru(phen′)(bbn)]
2+ complexes
(where phen′ = 1,10-phenanthroline and a variety of its
derivatives, see Figure 2) (Gorle et al., 2015; Sun et al.,
2018). Although some of these mononuclear complexes—
particularly cis-α-[Ru(Me4phen)(bb7)]
2+ (Me4phen = 3,4,7,8-
tetramethyl-1,10-phenanthroline), designated as α-Me4phen-
7; and cis-α-[Ru(phen)(bb12)]
2+, designated as α-phen-12—
showed good and uniform activity against both Gram-positive
and Gram-negative species, they were slightly less active than
the oligonuclear complexes to most bacteria (Sun et al., 2018).
However, while the toxicity toward eukaryotic cells has been
established for the oligonuclear complexes (Li et al., 2015b), the
corresponding data for the mononuclear complexes have yet to
be reported.
Another important factor governing the clinical potential of a
new compound is its ability to bind serum proteins (Kratochwil
et al., 2002; Bohnert and Gan, 2013; Liu et al., 2014). Blood serum
protein binding can affect the distribution and clearance of a drug
in several ways: only the free (non-protein bound) drug can act
as an antimicrobial agent; alternatively, non-protein bound small
drugs are cleared more rapidly from the bloodstream. Again,
while the binding of the oligonuclear complexes to human serum
albumin (HSA)–the most abundant serum protein (0.6mM
in healthy humans)–has been determined for the oligonuclear
complexes (Li et al., 2013b), it is yet to be reported for the
mononuclear complexes.
In the present study, we have determined the toxicity of
the mononuclear [Ru(phen′)(bbn)]
2+ complexes toward a panel
of eukaryotic cells and examined their HSA binding ability.
Furthermore, as encapsulation in cucurbit[n]urils {macrocyclic
host compounds composed of n glycoluril monomeric units,
Q[n]–see Figure 3 (Lagona et al., 2005; Kim et al., 2007; Isaacs,
2009)} can potentially decrease the toxicity of a drug and
modulate the drugs’ ability to bind serum proteins, (Wheate et al.,
2004; Jeon et al., 2005; Li et al., 2013b) we have also examined
the ability of α-Me4phen-7 to form an inclusion complex with
Q[10] and determined the subsequent effect on the toxicity of the
ruthenium complex toward eukaryotic cells and its ability to bind
HSA.
EXPERIMENTAL
Materials
The ruthenium complexes used in this study {cis-α-
[Ru(phen)(bb7)]
2+ (designated as α-phen-bb7), cis-α-
[Ru(Me2phen)(bb7)]
2+ (α-Me2phen-bb7), cis-α-[Ru(Me4-
phen)(bb7)]
2+ (α-Me4phen-bb7), cis-α-[Ru(NO2phen)(bb7)]
2+
(α-NO2phen-bb7), cis-α-[Ru(phen)(bb12)]
2+ (α-phen-bb12),
[Ru(Me4phen)3]
2+ and Rubb12} and Q[10] were synthesized as
previously described (Liu et al., 2005; Pisani et al., 2010; Gorle
et al., 2015; Sun et al., 2018).
Toxicity
The toxicities of the ruthenium complexes were assayed
against three eukaryotic cell lines: BHK (baby hamster
kidney); Caco-2 (heterogeneous human epithelial colorectal
adenocarcinoma); and Hep-G2 (liver carcinoma). All cell lines
were cultured in 75mL culture flasks in DMEM culture media
(Dulbecco’s Modified Eagle’s Medium, Gibco, Thermo Fisher,
UK) supplemented with 10% fetal bovine serum (Gibco, Thermo
Fisher, UK), 1% MEM Non-Essential Amino Acid (Sigma,
UK) and 1% penicillin-streptomycin (Sigma) at 37◦C in an
atmosphere of 5% humidified CO2. Cells used in the study were
in the logarithmic growth phase, and unless stated were grown to
70% confluence, and then trypsinized with 0.5% trypsin-EDTA
(Gibco, Canada) for detachment and use in the assays.
Half-maximal inhibitory concentrations (IC50) of the
ruthenium complexes against BHK, Caco-2 and HepG2 cell lines
were performed using the mitochondrial-dependent reduction
of 3-(3,4-dimethylthiazol-2-yl)-5-diphenyl tetrazolium bromide
(MTT) to formazan as previously described (Sundaraneedi
et al., 2017). The cells were cultured in 96-well microtiter plates
containing the respective media to a cell density of 3,000 per well
at 37◦C in an atmosphere of air containing 5% CO2. Cell viability
was assessed after continuous exposure to various concentrations
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FIGURE 1 | The structure of the bbn ligand and the associated oligonuclear ruthenium complexes.
of drugs (ranging from 0.5 to 400µM) for 24 and 48 h. Cisplatin
served as a treatment evaluation standard. Ruthenium complex
stocks were made to the required concentration in sterile
Milli-Q water, and cisplatin solutions were made to the required
concentration in culture medium before the treatment. The
amount of MTT reduced to formazan within the cells was
quantified by measuring the absorbance at λ = 570 nm using a
Fluostar GalaxyMicroplate Reader. The average values presented
are based on at least three independent experiments. The IC50
values were determined using GraphPad Prism 7.0 (GraphPad
Software, San Diego, USA).
HSA Binding
All solutions used in the protein binding studies were dissolved
in a 0.1M sodium phosphate buffer (pH= 7.4). Protein solutions
(5µM) were titrated with the ruthenium complexes from 2mM
stock solutions, from a metal complex/protein ratio of 0.0 to
8.0. The maximum fluorescence for HSA (Sigma-Aldrich) was
observed at λ = 345 nm after excitation at λ = 280 nm. All
experiments were carried out in triplicate, with results presented
as mean and standard deviation.
Encapsulation by Q[10]
NMR
1HNMR titrations were carried out by the addition of solid Q[10]
(0.4mg) into a solution of α-Me4phen-bb7 (2mM, 600 µL) to a
1:1 Q[10]:α-Me4phen-bb7 ratio. ROESY NMR experiments for
the free andQ[10]-encapsulated α-Me4phen-bb7 were conducted
with 2048 data points in t2 for 256 t1 values, with a pulse
repetition delay set to 1.7 s and mixing times of 350ms.
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FIGURE 2 | Structure and abbreviations for the cis-α-[Ru(phen′)(bbn)]
2+ complexes {n = 7; phen′ = 1,10-phenanthroline (phen); 4,7-dimethyl-1,10-phenanthroline
(Me2phen); 3,4,7,8-tetramethyl-1,10-phenanthroline (Me4phen); and 5-nitro-1,10-phenanthroline (NO2phen), n = 12; phen
′ = 1,10-phenanthroline}.
FIGURE 3 | Two representations of the structure of cucurbit[n]uril.
Molecular Modeling
The encapsulation of α-Me4phen-7 in the Q[10] cavity was
examined by molecular modeling using the HyperChem
(version 8, HyperCube, Inc.) program. The bb7 alkyl chain
was positioned deep within the Q[10] cavity and the
ruthenium metal center positioned at one of the portals
in a manner consistent with the NMR results. The Q[10]-
encapsulated α-Me4phen-7 was then optimized using the
Amber99 molecular mechanics forcefield without explicitly
treating water molecules (i.e., “in vacuo”). Successive geometry
optimizations using slightly different starting conformations
and different minimization algorithms produced similar
results.
Luminescence Titration
Spectra were recorded on a Horiba Scientific FluoroMax-
4 fluorescence spectrophotometer at room temperature in a
1 cm quartz cuvette. Samples were excited at λ = 435 nm
and emissions were recorded in the λ = 510–800 nm
range with slit widths of 5 nm in increments of 1 nm. All
luminescence spectroscopy samples were prepared in Milli-Q
water. Luminescence titrations were carried out by titration of 20
µL aliquots of Q[10] (12.5µM) stock solution into a α-Me4phen-
7 (0.675µM; 2,950 µL) solution to a 1.5:1 ratio. The sample
was then sparged with argon to remove any oxygen present and
allowed to equilibrate for 3min before measurements were taken.
The binding constant (Kb) for α-Me4phen-7 binding to Q[10]
was calculated using Equation 1 (Pisani et al., 2010):
Kb =
[MC]b
[MC]f × [Q10]f
(1)
where [MC]f and [Q10]f are the concentrations of free α-
Me4phen-7 and Q[10], respectively, at each titration point.
[MC]b was determined using Equation 2:
[MC]b =
[MC]t
1−
(
δobs−δb
δf (x)+δb(x)
) (2)
where [MC]t is the concentration of metal complex in the sample,
δobs is the luminescence intensity maxima observed at each
titration point, δb is the luminescence intensity maximum of the
bound metal complex, δf is the luminescence intensity maximum
of the free metal complex and x is the ratio of bound/free
metal complex at each titration point. The binding constant at
each point was calculated and averaged to give an approximate
binding constant.
Confocal Microscopy
The trypsinized BHK cells were seeded on sterile, poly L-lysine
coated, coverslips in a 24-well plate. The ruthenium complex
was applied to the cells in growth media to make the desired
concentration (25µM) and incubated at 37◦C with 5% CO2
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for 1 h. Following the incubation, 100 nM Mitotracker R© Green
FM (Invitrogen) was added for mitochondrial staining. Staining
was carried out in DMEM medium under standard cultivation
conditions as per the manufacturer’s instructions. Following
staining, the coverslips were gently rinsed with phosphate buffer
solution (PBS, pH = 7.1) prior to confocal laser scanning
microscopy.
The cellular accumulation of the ruthenium complex
was determined using a laser scanning confocal microscope
(FV3000, Olympus). Samples were viewed under 60× silicone
immersion using the following excitation (λex) and emission
(λem) wavelengths. Ruthenium complex (λex = 450 nm,
λem = 630 nm) and Mitotracker Green FM (λex = 490 nm,
λem = 516 nm) were excited using a blue argon laser
(λex= 488 nm), and emissions were collected atλ= 600–650 nm
for the ruthenium complex and λ= 500–550 nm for Mitotracker
Green. Image data acquisition and processing was performed
using Olympus FV31S-SW software. The luminescence intensity
of cis-α-[Ru(Me4phen)(bb7)]
2+ inside the BHK cells was
quantified using the surface rendering function of Imaris 9.2.1
software, and the data analyzed for statistical difference using the
Wilcoxon-test and t-test methods.
RESULTS
Toxicity Against Eukaryotic Cells
The toxicities of the [Ru(phen′)(bbn)]
2+ complexes against
three eukaryotic cell lines {baby hamster kidney (BHK), human
epithelial colorectal adenocarcinoma (Caco-2) and human
hepatocellular carcinoma (Hep-G2)} were determined and
compared to the values obtained for the dinuclear complex
Rubb12, [Ru(Me4phen)3]
2+ {designated (Me4phen)3, the most
active of the mononuclear complexes originally identified by
Dwyer and co-workers} and the control anticancer agent
cisplatin. The BHK and Hep-G2 cell lines were chosen so that
the IC50 results could be compared to those from our previous
studies with multinuclear ruthenium complexes (Li et al., 2015b).
It was also of interest to examine the toxicity of the ruthenium
complexes against a third eukaryotic cell line that was distinct
from kidney or liver cells—consequently, the Caco-2 cell line was
also used in this study. The results are summarized in Table 1.
The IC50 values determined for Rubb12 against the BHK and
Hep-G2 cell lines in this study were similar to those obtained
in an earlier study (Li et al., 2015b). Of note, α-Me4phen-7
showed no toxicity (>400µM) against BHK and Caco-2 cells,
and very low activity (≈ 150µM) against Hep-G2 cells for a 24-
h incubation and very low (BHK and Hep-G2) or no toxicity
(Caco-2) for a 48-h incubation. By contrast, α-phen-12 was
(2–5)-fold more toxic than α-Me4phen-7, while Rubb12 was
generally much more toxic to the eukaryotic cells than either of
the mononuclear complexes.
HSA Binding
The binding of the [Ru(phen′)(bbn)]
2+ complexes to human
serum albumin (HSA) was examined by fluorescence
spectroscopy. HSA has one fluorescent tryptophan residue
that can be used as a fluorophore in drug-binding experiments.
TABLE 1 | IC50 values (µM) of the ruthenium complexes against the BHK,
Hep-G2 and Caco-2 cell lines for 24- and 48-h incubations.
Complexes BHK Hep-G2 Caco-2
24 h 48 h 24 h 48 h 24 h 48 h
α-phen-7 >400 250 ± 42 319 ± 26 312 ± 15 >400 219 ± 43
α-Me2phen-7 >400 250 ± 46 358 ± 18 151 ± 30 >400 >400
α-Me4phen-7 >400 168 ± 5 162 ±14 142 ± 8 >400 >400
α-NO2phen-7 >400 >400 141 ± 29 99 ± 29 121 ± 18 126 ± 6
α-phen-12 92 ± 26 85 ± 16 94 ± 13 19 ± 3 227 ± 22 177 ± 17
(Me4phen)3 157 ± 25 111 ± 23 253 ± 60 72 ± 31 220 ± 43 265 ± 13
Rubb12 44 ± 9 41 ± 7 55 ± 12 15 ± 5 10 ± 1 8 ± 3
Cisplatin >400 146 ± 8 314 ± 8 12 ± 3 376 ± 41 25 ± 6
Q[10]-α-
Me4phen-7
>400 >400 >400 >400 >400 >400
The relative changes in HSA fluorescence upon binding of
selected ruthenium complexes are shown in Figure 4.
All ruthenium complexes showed significant binding affinity
with HSA. Consistent with a previous HSA binding study of the
Rubbn complexes (Li et al., 2013b), the decrease in the tryptophan
fluorescence was found to be due to static quenching, a positional
change of the tryptophan residue induced by the binding of the
ruthenium complex to the protein.
The static quenching via binding of the ruthenium complexes
to HSA can be represented as:
nRu+HSA→ nRu···HSA
where nRu...HSA denotes the quenched ruthenium
complex/HSA species. A double-logarithm equation of
log10[(F0-F)/F] vs. log10[Ru] can then be used to express
the equilibrium between the free and bound ruthenium(II)
complex to determine the apparent binding constant (Kapp) and
the binding number (n) (Krause-Heuer et al., 2012).
log
[
F0 − F
F
]
= log10 Kapp + n log10 [Ru]
It was not possible to determine a single apparent HSA binding
constant, as a linear relationship was not observed over the entire
concentration range of added ruthenium complex in the plot
of log10[(F0 – F)/F] vs. log10[Ru]. However, two distinct linear
sections could be found in the analysis of the double logarithm,
corresponding to ruthenium complex to HSA ratios of (a) 0 to
2.4 and (b) 2.4 to 8. As previously observed (Li et al., 2013b), the
two binding ratio regions represent an initial 1:1 binding at low
ruthenium complex concentration (ratios 0–2.4), and then upon
addition of further ruthenium complex, a region (2.4–8) where
multiple ruthenium complexes (≥ 2:1) are bound to HSA. The
higher affinity 1:1 HSA binding constant Kapp and the binding
numbers n for the ruthenium complexes determined at low ratios
of added ruthenium complex are summarized in Table 2.
For the [Ru(phen′)(bb7)]
2+ complexes, the HSA binding
affinity increased with the number of methyl substituents on
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FIGURE 4 | Top: relative change in the HSA fluorescence upon binding
α-Me4phen-7, α-NO2phen-7 and α-phen-12; bottom: the log plot of
cis-α-[Ru(Me4phen)(bb7)]
2+ binding with HSA at low α-Me4phen-7 to HSA
ratios.
the 1,10-phenanthroline ligand; however, the α-NO2phen-bb7
complex showed the highest binding affinity. Interestingly, the α-
Me4phen-7 complex boundHSAwith significantly higher affinity
than the [Ru(Me4phen)3]
2+ and α-phen-bb12 complexes, and
with approximately the same affinity as previously determined
for Rubb12 (Kapp = 4.7× 10
5 M−1) (Li et al., 2013b).
Q[10] Encapsulation of α-Me4phen-7
NMR Studies
As α-Me4phen-7 exhibited the best differential (≈ 20-fold)
between high antimicrobial activity (previously demonstrated in
Sun et al., 2018) and low toxicity, it was selected for the Q[10]
binding studies. Figure 5 shows the 1H NMR spectrum of α-
Me4phen-7 and the spectra of the metal complex with added
Q[10] at various Q[10] to α-Me4phen-7 ratios (R). The
1H NMR
resonances of α-Me4phen-7 and the Q[10]-bound ruthenium
complex were assigned from a combination of DQFCOSY and
ROESY experiments. In particular, the resonances from the bb7
ligand were assigned through the observation of an ROE from
the spin-coupled bpy H5 and H5’ protons (coupled to the H6
TABLE 2 | The n and Kapp values for the HSA binding of the ruthenium
complexes at a [Ru complex]/[HSA] ratio from 0 to 2.4.
Complex n Kapp × 10
5 (M)−1 R2
(Me4phen)3 0.81 0.12 ± 0.03 0.98
α-Me4phen-7 1.14 4.6 ± 0.90 0.996
α-Me2phen-7 0.91 0.29 ± 0.13 0.984
α-phen-7 0.80 0.10 ± 0.00 0.991
α-NO2phen-7 1.27 23.5 ± 4.9 0.998
α-phen-12 0.95 0.43 ± 0.17 0.993
and H6’ protons) to the substituted-bpy ligand methyl (Me) and
chain methylene protons respectively. The bpy H3 and H3’ were
similarly assigned from the observed ROEs to the bpy Me and α-
CH2 protons, respectively. The phenanthroline H2/9 resonances
were assigned through the observation of an ROE to the bb7 H6
protons.
One set of exchange-broadened resonances was observed
for the protons from both α-Me4phen-7 and Q[10], indicating
intermediate-exchange kinetics on the NMR timescale at 25◦C
for R < 1. Of note, the resonances from the CH2 groups in the
alkyl chain of the bb7 ligand shifted significantly upfield (0.3–
0.5 ppm). This indicates the alkyl chain is positioned deep within
the Q[10] cavity, as many previous studies have established that
resonances from guest protons located inside a Q[n] cavity shift
significantly upfield, with protons positioned toward the middle
of the Q[n] cavity exhibiting the largest (up to 1 ppm) upfield
shifts (Mock and Shih, 1986; Jeon et al., 1996). This suggests
that α-Me4phen-7 binds Q[10] with the bb7 ligand deep within
the cavity and the Me4phen ligand projecting out of the portal.
Consistent with this proposal are the significant upfield shifts
(≈ 0.5 ppm) for the bb7 protons on the pyridyl ring containing
the alkyl chain (H3’, H5’ and H6’) coupled with the observed
downfield shifts of the Me4phen H2/9 and H5/6 resonances.
Interestingly, at a Q[10] to α-Me4phen-7 ratio of 1 (as
determined from the integration of the respective resonances),
two sets of resonances for the bb7 aromatic protons and the Q[10]
CH2 resonances were observed (see Figures 5, 6), indicating
slow-exchange binding kinetics. The inequivalence of the Q[10]
methylene resonances that project toward the portals (5.83 and
5.64 ppm) and toward the cavity center (4.23 and 4.14 ppm)
is due to the non-symmetric encapsulation of α-Me4phen-7 in
Q[10]. As intermediate-exchange kinetics were observed at R< 1
but slow-exchange at R = 1, it is concluded that for all values of
R < 1 there must be some 1:2 (Q[10] to α-Me4phen-7) binding
with the rate of exchange between the 1:1 and 1:2 binding modes
being in the fast-exchange regime. In the R = 1 spectrum, the
resonances from the bpy CH3 groups were also inequivalent, with
one peak shifted downfield and the other upfield compared to
equivalent bpy CH3 resonances in the free ruthenium complex.
This suggests that one bpy CH3 is positioned inside the Q[10]
cavity with the second bpy CH3 located outside of the portal.
Possibly due to the broadness of the resonances from α-
Me4phen-7, very few intermolecular ROEs were observed in
ROESY spectra of the Q[10]-encapsulated ruthenium complex.
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FIGURE 5 | 1H NMR spectrum of the aromatic region of the free α-Me4phen-7 (C) and with added Q[10], at Q[10] to α-Me4phen-7 ratios of 0.75 (B) and 1.0 (A).
FIGURE 6 | 1H NMR spectrum of the protons from Q[10], at Q[10] to α-Me4phen-7 ratios of 0 (bottom spectrum), 0.75 (middle) and 1.0 (top).
However, ROEs was observed from the Me4phen H2/9 and 3/8
methyl resonances to the Q[10] methylene protons that project
toward the portal.
Molecular Modeling
In order to confirm the feasibility of the mode of binding
suggested by the NMR data, the encapsulation of α-Me4phen-7
within the Q[10] cavity was examined by molecular simulations
using the HyperChem modeling software. The methylene chain
of α-Me4phen-7 was folded within the Q[10] cavity and the
ruthenium metal center positioned at the portal in a manner
consistent with the observed intermolecular ROEs observed in
ROESY spectra. The system was then successively optimized
using the Amber99 molecular mechanics forcefield. As shown in
Figure 7, stable low energy conformations could be obtained with
the methylene chain folded in the cavity and the rutheniummetal
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FIGURE 7 | Molecular modeling of the encapsulation of α-Me4phen-7 with
Q[10] using HyperChem software. The color of the atoms of α-Me4phen-7 are:
H, white; C, cyan; N, blue; and Ru, red.
FIGURE 8 | The luminescence decrease of α-Me4phen-bb7 upon the addition
of Q[10] to a Q[10] to α-Me4phen-7 ratio of 1.5.
center positioned outside the portal consistent with the NMR
data.
Luminescence Spectroscopy
In order to obtain an equilibrium binding constant, the
association of α-Me4phen-7 with Q[10] was studied by
luminescence spectroscopy. The luminescence intensity of α-
Me4phen-7 decreased upon the addition of each aliquot of Q[10]
up to R = 1.5 (see Figure 8). Binding curves were generated by
plotting luminescence intensity (counts per second) against the
molar ratio of added Q[10], from which a 1:1 binding constant of
9.9± 0.2× 106 M−1 was determined.
Biological Properties of α-Me4phen-7 Encapsulated
in Q[10]
Upon encapsulation in Q[10], α-Me4phen-7 exhibited no toxicity
to any of the cell lines for both 24- or 48-h incubations (see
FIGURE 9 | Relative change in the HSA fluorescence upon binding
α-Me4phen-7 and α-Me4phen-7 encapsulated in Q[10].
Table 1). Based upon the 48-h incubation toxicity to BHK and
Hep-G2 cells, it can be concluded that Q[10]-encapsulation
decreases the toxicity of α-Me4phen-7 by at least (2–3)-fold. Of
note, and contrary to what was observed for Rubb12, Q[10]-
encapsulation increases the affinity of α-Me4phen-7 for HSA (see
Figure 9). A Kapp of 2 ± 0.2 × 10
6 M−1 was determined for the
Q[10]-encapsulated ruthenium complex.
Reducing the cellular accumulation of α-Me4phen-7 is the
simplest mechanism by which Q[10]-encapsulation could reduce
toxicity. Consequently, confocal microscopy was used to obtain
both a qualitative and quantitative measure of the effect of Q[10]-
encapsulation on the cellular accumulation of α-Me4phen-7 in
BHK cells after a short incubation time. Figure 10 shows confocal
microscopy images of BHK cells after a 1 h incubation with free
or Q[10]-encapsulated α-Me4phen-7. Mitotracker Green (which
selectively localizes in the mitochondria) was used to visualize
the cells, with the nucleus of the cell being the dark circular
region outlined by the green luminescence. As it appeared
that the cellular accumulation was not significantly different
between the free or Q[10]-encapsulated α-Me4phen-7 samples,
the luminescence intensity from α-Me4phen-7 per cell was
quantified over all the images taken. The results are shown in
Figure 11. As seen in the “box and whiskers” diagram, and
confirmed by statistical analysis (Wilcoxon-test and a t-test;
p = 0.13 and 0.11, respectively), there was no difference in the
level of the cellular accumulation of α-Me4phen-7 between the
experiments where the ruthenium complex was added to the
BHK cells in either the free or Q[10]-encapsulated forms.
DISCUSSION
We have previously shown that some mononuclear
ruthenium(II) complexes containing bbn as a tetradentate
ligand (particularly α-phen-12 and α-Me4phen-7) exhibit
good antimicrobial activity (MICs = 1–10µM) against both
Gram-positive and Gram-negative bacteria (Gorle et al., 2015;
Sun et al., 2018). In this study we have examined their associated
toxicity to eukaryotic cells. Importantly, although α-Me4phen-7
was as active against Gram-negative bacteria as α-phen-12 (Sun
et al., 2018), the results from the present study showed that
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FIGURE 10 | Top, left to right: α-Me4phen-7 accumulation in BHK cells at
25µM after a 1-h incubation, stained by Mitotracker Green and α-Me4phen-7
(red). Bottom, left to right: Q[10]-encapsulated α-Me4phen-7 accumulation in
BHK cells at 25µM after a 1-h incubation, stained by Mitotracker Green and
α-Me4phen-7 (red). Scale bar = 10µm.
FIGURE 11 | “Box and whisker” plot of the luminescence from α-Me4phen-7
accumulation in BHK cells at 25µM after a 1-h incubation for both free and
Q[10]-encapsulated α-Me4phen-7. The red box region shows the 25–75%
quartiles for the luminescence intensity per cell, while the whiskers show the
maximum and minimum intensities per cell.
α-Me4phen-7 was (2–5)-fold less toxic to eukaryotic cells than
α-phen-12. It was also previously shown that α-phen-12 (log
P = −0.9) accumulated in bacterial cells more rapidly and
to a greater degree than did α-Me4phen-7 (log P = −1.33),
consistent with their respective lipophilicities (Sun et al., 2018).
Consequently, α-Me4phen-7 appears to be more toxic to Gram-
negative bacteria than α-phen-12 on a molar basis. This could
be due to the greater DNA binding ability of α-Me4phen-7,
compared to α-phen-12 (Sun et al., 2018). Of relevance in the
present study, the preliminary confocal microscopy experiments
indicated that α-Me4phen-7 did not localize in the nucleus
of BHK cells. As a consequence, α-Me4phen-7 might not be
inherently more toxic to eukaryotic cells than α-phen-12. Hence,
based upon lipophilicity, it would be expected that α-phen-12
would also accumulate to greater degree in eukaryotic cells than
α-Me4phen-7, and thereby be more toxic. It was also noted
that α-Me4phen-7 was significantly less toxic than the lead
oligonuclear complex, Rubb12. In absolute terms, α-Me4phen-7
showed very little toxicity to the eukaryotic cells and was found
to be at least 20-fold more active against Gram-negative bacteria
(Sun et al., 2018) than eukaryotic cells over a 24 h time period.
In terms of HSA binding, α-Me4phen-7 bound the serum
protein approximately 10-fold more tightly than α-phen-12 and
α-Me2phen-7, and with similar affinity as Rubb12. Previous
studies have demonstrated that there are a number of factors
governing the binding affinity of drugs with HSA (Kratochwil
et al., 2002; Bohnert and Gan, 2013; Liu et al., 2014). Lipophilicity
is generally considered to be important, particularly within a
series of structurally-related compounds. In this study it was
found the degree of methylation of the phenanthroline ligand,
and hence lipophilicity, did correlate with stronger binding.
However, the α-NO2phen-7 complex (log P = −1.58) bound
HSA with higher affinity than α-Me4phen-7 (log P = −1.33).
This observation suggests that the dispersion of the 2+ charge
of the ruthenium complex is also important, which is consistent
with the approximate charge of HSA at physiological pH being
−17 (Fogh-Andersen et al., 1993).
It is often assumed that low serum protein binding is a “good”
drug property, as it increases the concentration of the free drug;
however, in a recent survey of newly approved drugs, Liu and
co-workers (Liu et al., 2014) found that 45 and 24% of the
drugs exhibited high (>95% bound) or very high (>99%) serum
protein binding, respectively. Consequently, Liu et al and others
proposed that serum protein binding is neither an intrinsically
“good” or “bad” property. However, a recent pharmacokinetic
study of Rubb12 in mice demonstrated that the amount of the
ruthenium complex in the serum decreased very rapidly after
administration by intravenous injection (Li et al., 2017). This
result suggests that potential new ruthenium complexes would
need to bind serum proteins at least as strongly, if not with greater
affinity, than Rubb12. Based upon this criterion, it is noted that
α-Me4phen-7 binds HSA with at least similar affinity to Rubb12.
Given the antimicrobial potential of α-Me4phen-7, it was of
interest to examine the ability of the ruthenium complex to bind
Q[10], and determine its subsequent effect on cytotoxicity and
HSA binding. The results of this study showed that α-Me4phen-
7 does form a high-affinity water-soluble association complex
with Q[10], with the bb7 alkyl chain positioned deep within
the cavity and the ruthenium metal center positioned at one
of the portals. This binding mode, with the non-polar segment
of a metal complex in the hydrophobic cavity and the cationic
metal center positioned at the carbonyl-rimmed hydrophilic
portals, is consistent with previous studies (Pisani et al., 2010;
Alrawashdeh et al., 2016). The magnitude of the α-Me4phen-
7-Q[10] binding constant (≈107 M−1) indicates that a large
proportion of the ruthenium complex would be Q[10]-bound at
the micro-molar concentrations that would be found in the blood
after administration.
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The effect of Q[n] encapsulation on the cytotoxicity of a
variety of compounds toward eukaryotic cell lines has been
previously examined. For example, Kim et al. reported a (5–10)-
fold decrease in activity for oxaliplatin in Q[7] (Jeon et al., 2005),
while Wheate et al showed that a dinuclear platinum complex
maintained its activity toward L1210 cells, but was 2-fold less
active against the cisplatin resistant cell line L1210/DDP (Wheate
et al., 2004). Furthermore, there have been several recent reports
where encapsulation in Q[n] was proposed to have increased the
uptake of a cytotoxic agent (Konda et al., 2017; Shinde et al.,
2018). In the present study, Q[10]-encapsulation decreased the
toxicity of α-Me4phen-7 toward BHK and Hep-G2 cells, while
no conclusions could be drawn for the Caco-2 cells, given the
lack of activity of the free ruthenium complex for both 24-
and 48-h incubations. The most obvious explanation for the
decreased toxicity of α-Me4phen-7 encapsulated in Q[10] is that
the concentration of the free, unbound, ruthenium complex is
significantly lower in the assay medium and the Q[10]-bound
ruthenium complex can not cross the cell membrane. This would
consequently result in a slower and lower accumulation of the
ruthenium complex inside the cells. However, the results from
the confocal microscopy experiments indicated that the level of
accumulation of α-Me4phen-7 inside the cells is not significantly
affected by encapsulation over a 1-h incubation.
In terms of HSA binding, Q[10]-encapsulation increased the
affinity of α-Me4phen-7 for the serum protein. Interestingly, in
an earlier study it was determined that Q[10]-binding of Rubb12
decreased the affinity of the ruthenium complex for HSA binding
(Li et al., 2013b). As noted above, given the short residence
time found for Rubb12 after intravenous injection in mice, the
(3–4)-fold higher HSA binding affinity is likely to be beneficial.
CONCLUSIONS
In conclusion, the results of this study have demonstrated
that the most active antimicrobial mononuclear ruthenium
complex against Gram-negative bacteria, α-Me4phen-7, is also
the least toxic to eukaryotic cells. Furthermore, although it
exhibits slightly lower (≈ 2-fold) antimicrobial activities to
Gram-negative bacteria than the lead oligonuclear complex
Rubb12 (Sun et al., 2018), α-Me4phen-7 is also significantly less
toxic to eukaryotic cells compared to the dinuclear complex.
Fluorescence assays demonstrated that α-Me4phen-7 bound
HSA with similar affinity to that previously reported for Rubb12.
Taken together, the results of this study suggest α-Me4phen-7
is a suitable candidate for further studies of its antimicrobial
properties. In addition, it has been shown that α-Me4phen-7
can form a high-affinity, water-soluble, inclusion complex with
Q[10]. Q[10]-encapsulation decreases the toxicity of α-Me4phen-
7 toward eukaryotic cells and increases its HSA binding affinity.
As a consequence, administration of α-Me4phen-7 encapsulated
in Q[10] may increase the potential of the ruthenium complex
as an antimicrobial agent. However, the effect of Q[10]-
encapsulation on the antimicrobial properties of α-Me4phen-7
needs to be examined.
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